| 1 |
33433610 | PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. | 2021 Jun 1 |
6 |
| 2 |
34182476 | The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model. | 2021 Jul-Aug |
1 |
| 3 |
31133874 | PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination With Cisplatin or Temozolomide in B16F10 Melanoma Cells. | 2019 |
2 |
| 4 |
30153289 | ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. | 2018 |
2 |
| 5 |
30252484 | ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461. | 2018 Nov 5 |
2 |
| 6 |
30416757 | Autophagy modulates temozolomide-induced cell death in alveolar Rhabdomyosarcoma cells. | 2018 |
1 |
| 7 |
28543772 | PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. | 2017 Sep |
1 |
| 8 |
28947502 | Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. | 2017 Dec |
3 |
| 9 |
26936394 | Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model. | 2016 Feb |
3 |
| 10 |
26438157 | Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. | 2015 Dec |
1 |
| 11 |
25434381 | Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. | 2014 Dec |
1 |
| 12 |
22287547 | PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. | 2012 Apr 1 |
1 |
| 13 |
21617871 | Effect of temozolomide on cell viability in gonadotroph adenoma cell lines. | 2011 Sep |
1 |
| 14 |
20464779 | Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent. | 2010 Jun |
11 |
| 15 |
18440222 | Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. | 2008 Jun |
1 |
| 16 |
18674509 | An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. | 2008 Oct 15 |
1 |
| 17 |
15645126 | Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. | 2005 Feb |
4 |
| 18 |
16170028 | Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. | 2005 Sep |
4 |
| 19 |
16288862 | Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. | 2005 Dec |
7 |
| 20 |
12855651 | Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. | 2003 Jul |
1 |
| 21 |
14614022 | Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. | 2003 Nov 1 |
3 |
| 22 |
7547230 | Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. | 1995 Oct |
1 |